EDIT Editas Net Sales Margin

Editas Medicine Inc - graphic logo of issuer EDIT

Editas Medicine, Inc. (EDIT) combines an elite team of geneticists with cutting-edge R&D to create CRISPR therapies that correct hereditary pathologies at the DNA level. The net profit margin reflects the business's efficiency dynamics, where -145.00 serves as the current metric level. The implementation of automated laboratories is currently accelerating the development of gene products, optimizing the path of innovation to market.

Editas Corp (EDIT) Net Return on Sales: for the period 07/04/2022 - 11/20/2026

Editas (EDIT) - metric breakdowns and financial figures

- share price and expert price forecast:
Analysis of all company metrics:Editas Medicine, Inc.
Finished products of Editas Medicine Inc

Assessing the investment reliability of an asset requires an objective profitability analysis to avoid overpaying for temporary spikes in earnings. The net income-to-revenue ratio determines the efficiency of each unit of income, which for Editas Medicine, Inc. (EDIT) reflects the cost of maintaining a highly qualified staff of biologists; consequently, the net profit margin demonstrates the company's ability to convert scientific patents into financial stability.

Key competitors

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX